Daniel Barvin, MBA, is vice president of operations and patient advocacy at Coya Therapeutics, where he ensures patient perspectives are central to clinical development and company strategy. As the company’s first employee, Barvin helped build Coya’s operational foundation, patient engagement model and clinical readiness strategy. Today, he plays a key role in preparing for Coya’s Phase II ALS trial with its investigational therapy, COYA 302.
In his current role, Barvin serves a dual function that uniquely combines internal strategic oversight with external community engagement. On the operations side, he works cross-functionally to support Coya’s clinical programs, manage internal infrastructure and align the company’s day-to-day work with long-term goals. Externally, Barvin leads patient engagement efforts, fostering strong partnerships with the ALS community. He ensures patients and families are connected to updates, educational resources and company initiatives, strengthening trust and collaboration between Coya and those impacted by ALS.
Barvin’s work is deeply personal—he carries the C9orf72 mutation linked to ALS and frontotemporal dementia (FTD) and has lost multiple family members to the diseases. This experience drives his mission to accelerate progress for the ALS community and reshape how biotech companies collaborate with patients.
Key Achievements
- Guided the transition of Coya from an early-stage startup into a publicly-traded biotech
- Ran the company alongside the CEO for its first two years, contributing to all major projects through its early growth phase
- Helped establish Coya’s C-suite and operational infrastructure as the company matured
- Received the ALS Association’s ALS Heroes Award in 2025 for distinct impact on the ALS community
- Co-founded Genetic ALS and FTD: End the Legacy, a nonprofit supporting hereditary ALS families